US Food and Drug Administration (FDA) Approved JOURNAVX (Suzetrigine) oral tablets are the first non -opioid analgesic in class to treat adult acute pain on Thursday.
“Today's approval is an important public health milestone in acute pain management,” said Jacqueline Korigan Snowfish, a deputy director of the FDA drug evaluation research center.
“The new non -opioid analgesic treatment class for acute pain provides an opportunity to ease specific risks related to using opioids for pain, and provides another treatment option to patients.” 。
Corrigan-Curay said that the approval emphasized the commitment of institutions for “safety” and “effective” alternatives for pain management.
New development is groundbreaking to provide an opioid alternative. Every year, tens of millions of Americans are prescribed opioids such as Hydrokodon, Oxycodon, and Fentanyl.
Approximately 10,000 people were killed by overdose of drugs in 2022, killing about 82,000 or 76 % of the death due to the use of opioids. American Disease Prevention Management Center。
After the FDA approval, SUZETRIGINE became the first new painkiller approved in the United States for the first time in 27 years.
JOURNAVX was evaluated in two randomization comparison tests of acute surgical pain. According to the FDA, both tests showed statistically significant pain -indicating pain with JOURNAVX compared to placebo.
A 50 -milligram prescription drug, including drug sediatrigin, is taken every 12 hours of a larger starter dose.
